Introduction
P eptide nucleic acids (PNAs) are a new class of antisense DNA analogs that have no sugar phosphate backbone and display high af nity for complementary RNA and DNA sequences (Nielsen et al., 1991; Uhlmann, 1998; Koppelhus and Nielsen, 2003) . We have shown that PNAs targeted to the primer binding site and A-loop sequences in the U5-PBS region of the HIV-1 genome block the initiation of reverse transcription (Lee et al., 1998) , strongly destabilize the priming of natural tRNA 3 Lys primer with the viral genome, and inhibit HIV-1 replication (Kaushik and Pandey, 2002) . We have further demonstrated that anti-HIV-1 PNA targeted to the transactivation response (TAR) element of HIV-1 LTR when transfected into HIV-1-infected cells prevents Tat-TAR interaction and blocks not only Tat-mediated transactivation of HIV-1 LTR transcription (Mayhood et al., 2000) , but also HIV-1 production (Kaushik et al., 2002a (Kaushik et al., , 2002b ). These studies demonstrate the therapeutic potential of PNA for intervention in HIV-1 replication and production by targeting multiple critical regions of the viral genome. However, poor cellular uptake of PNA has been a major impediment in the development of this class of compounds as therapeutic agents. Various approaches have been adopted for the ef cient biodelivery of PNA into cells, including conjugation to lipophilic moieties (Ljungstrom et al., 1999; Muratovska et al., 2001) , cell-speci c receptor ligands (Basu and Wickstrom, 1997; Boffa et al., 2000; Zhang et al., 2001) , carrier peptides (Cutrona et al., 2000) , neamine (Riguet et al., 2004) , and guanidine-based PNA (Zhou et al., 2003) electrostatically bound with the polymeric core shell microsphere (Chiarantini et al., 2005) or loaded into the autologous red blood cells (Chiarantini et al., 1995; Turrini et al., 1991) . We have demonstrated that polyamide nucleic acids complementary to the transactivation response (TAR) element of HIV-1 LTR inhibit HIV-1 production when transfected in HIV-1 infected cells. We have further shown that anti-TAR PNA (PNA TAR ) conjugated with cell-penetrating peptide (CPP) is rapidly taken up by cells and exhibits strong antiviral and anti-HIV-1 virucidal activities. Here, we pharmacokinetically analyzed 125 I-labeled PNA TAR conjugated with two CPPs: a 16-mer penetratin derived from antennapedia and a 13-mer Tat peptide derived from HIV-1 Tat. We administered the 125 I-labeled PNA TAR -CPP conjugates to male Balb/C mice through intraperitoneal or gavage routes. The naked 125 I-labeled PNA TAR was used as a control. Following a single administration of the labeled compounds, their distribution and retention in various organs were monitored at various time points. Regardless of the administration route, a signi cant accumulation of each PNA TAR -CPP conjugate was found in different mouse organs and tissues. The clearance pro le of the accumulated radioactivity from different organs displayed a biphasic exponential pathway whereby part of the radioactivity cleared rapidly, but a signi cant portion of it was slowly released over a prolonged period. The kinetics of clearance of individual PNA TAR -CPP conjugates slightly varied in different organs, while the overall biphasic clearance pattern remained unaltered regardless of the administration route. Surprisingly, unconjugated naked PNA TAR displayed a similar distribution and clearance pro le in most organs studied although extent of its uptake was lower than the PNA TAR -CPP conjugates.
Iodination of PNA TAR -CPP conjugates
We radiolabeled the PNA TAR -CPP conjugates and PNA TAR with 125 I, using Na 125 I and a chloramine-T-labeling kit from ICN (Costa Mesa, California). For radiolabeling, 0.5 nmol of the conjugate and 0.28 nmol of 125 I (0.5 mCi) were reacted in the presence of 2.8 nmol of chloramine-T for 1 minutes; labeling was quenched by the addition of 62 nmol of sodium metabisulphite according to manufacturer's protocol. We puri ed the labeled conjugate by NAP-10 gel ltration (GE Healthcare Bio-Sciences, Piscataway, NJ, USA), then by C 18 reverse phase columns. The labeled conjugate was quantied by absorption at 260 nm. The speci c radioactivity was adjusted to the desired concentration by adding unlabeled conjugate.
Animals
Male Balb/c mice 6-8 weeks old were purchased from Taconic Farms (Germantown, NY, USA) and quarantined for 2 weeks before the start of the experiment. The weight variation of individual mice was within ±10% of the mean body weight. The mice were fed lab-diet certi ed rodent diet. Food and water were available ad libitum. The mice were housed in a room with a temperature of 70 ± 3 o F, relative humidity of 31-62%, and a 12-hours light/dark cycle. All treatment of mice was done according to the Guide for the Care And Use of Laboratory Animals, as per a protocol approved by the Institutional Animal Care and Use Committee of the UMDNJ. Every precaution was taken to ensure the welfare of animals at all times during the entire course of study.
Pharmacokinetic protocol
Mice were randomly assigned to eight time groups of ve mice per group; each group was housed in a separate cage for pharmacokinetic studies. Each mouse was given an IP injection of 200 µL of a solution containing 36 nmol of labeled PNA TAR or its conjugate derivative (1.5 × 10 6 CPM) in phosphate-buffered saline (PBS). Similar dose was given for oral gavage. The mice were euthanized at various times. We then collected different organs and tissues (kidney, intestine, stomach, liver, spleen, lungs, brain, heart, and skeletal muscle), rinsed them in PBS, wiped them with lter paper, and weighed them, after which the accumulated radioactivity in each sample was counted. Blood was also collected from each animal, weighed, and counted for radioactivity. The radioactivity was counted with a Packard Cobra model 5003 automatic gamma counter equipped with a 3-inch sodium iodide well crystal ( 125 I T 1/2 ~ 60 d; energy ~ 35 keV; overall counting ef ciency ~ 0.88).
To determine the radioactivity excreted in urine, groups of three mice were placed in a polycarbonate cage lined with lter paper (Schleicher & Schuell Bioscience, NH, USA). Animals were moved to fresh cages at 4-hours intervals. Filter papers from the emptied cage were cut into pieces, after which their radioactivity was counted. Feces were also collected and counted separately without any further treatment.
We have used cell-penetrating peptides (CPPs) as the vector to deliver PNA cargo into cells. Anti-HIV-1 PNAs conjugated with CPP are ef ciently taken up by cells; they also effectively block HIV-1 replication and viral production by HIV-1 infected cells (Kaushik et al., 2002a; Chaubey et al., 2005; Tripathi et al., 2005) . We have further shown that anti-HIV-1 PNA TAR -CPP conjugates are potent virucidal agents that are able to penetrate virion particles and render them noninfectious Tripathi et al., 2007) . Unexpectedly, PNA TAR -CPP conjugates are nontoxic and well tolerated at higher doses when administered in mice (Chaubey et al., 2008) . With the improved solubility and cellular uptake of PNA TAR -CPP conjugates, further studies pertaining to their pharmacokinetic behavior, in vivo tissue distribution, and immune response, are necessary to establish PNA as potential therapeutic agents. In the present study, we have evaluated the tissue distribution and pharmacokinetic behavior of 
Methods and Materials

Synthesis of PNA TAR -CPP conjugates
Cys-PNA TAR monomers and NPYS-Cys-derivative of Penetratin and Tat peptide ( Fig. 1) were synthesized by BioSynthesis (Lewisville, TX, USA). We conjugated the NPYSCys-peptides with Cys-PNA TAR using standard disul de chemistry as described by Kaushik et al. (2002a) , Koppelhus et al. (2002) , and Tripathi et al. (2005) . The C-terminal of PNA TAR had a terminal tyrosine residue for iodination with 125 I (Fig. 1) . In PNA TAR -O-penetratin purchased from BioSynthesis, penetratin peptides (43-58) were synthesized in tandem after the synthesis of PNA TAR carrying ethylene glycol linker-Tyr at the N-terminus (Fig. 1 ). Kidney and liver tissues were collected, washed with saline solution and homogenized in a buffer (1.5 mL/gm tissue) consisting of 20 mM Tris, pH 7.5, 0.1M EDTA, and 0.15% NP-40. Samples were centrifuged at 14,000 rpm for 10 minutes. The supernatant was acidi ed to pH 4.0 with 5% TFA and centrifuged again at 14,000 rpm for 10 minutes. The clear supernatant was applied on disposable Sep-Pak reverse phase C 18 cartridges (Waters, Milford, MA, USA) preequilibrated with 5% acetonitrile in 0.1% TFA. The column was washed extensively with 5% acetonitrile/0.1% TFA. The PNA bound to the column was eluted with 60% acetonitrile in 0.1% TFA at 50 o C. An aliquot of each sample was analyzed by mass spectrometry using Applied Biosystems 4700 Proteomics Analyzer 7000. The remaining samples were lyophilized, dissolved in PBS, and subjected to gel-retardation assay as described in Chaubey et al. (2007) .
Results
Distribution of unconjugated naked PNA TAR and its CPP conjugates in different organs after administration by IP injection or gavage
We administered 125 I-labeled naked PNA TAR or PNA TAR -CPP conjugated with either penetratin or Tat peptide to male Balb/C mice by IP injection. For gavage, we used 125 I-labeled naked PNA TAR and two derivatives of PNA TAR -penetratin conjugates. One of these derivatives had disul de linkage between PNA TAR and the peptide; the other had covalent linkage via an o-linker (Fig. 1) . The main reason for not including PNA TAR -Tat conjugate in the gavage is that Lys and Arg rich Tat peptide may be susceptible to trypsin in the intestine.
We then sacri ced the mice at different time intervals and counted the radioactivity accumulated in each organ
Pharmacological data analysis
The radioactivity accumulated in a mouse organ tissue and the total organ weight were used to calculate the percent of administered radioactivity per gram of tissue (%AA/g) at each time point where %AA Organ radioactivity Injected radioactivity Organ weight g ϭ
The resulting data for each radiolabeled compound were least squares tted to a two-component exponential function expressed as
where T1 and T2 are the biological half-times of the fast-and slow-clearing components, respectively. The two-component tting procedure was performed using SigmaPlot software from SPSS (Chicago, IL, USA). The pharmacokinetic coef cients a and b, along with their associated half-time parameters T1 and T2, are given in the tables for different organs (Tables 1-4 ). The uncertainties associated with each parameter (∆) in the tting procedure are listed in the same tables. R 2 is the coef cient of determination; the most common measure of how well a regression model describes the data. R 2 values near 1 indicate that the equation is a good description of the relationship between the dependent and independent variables.
Tissue stability of PNA TAR -peptide conjugate
Balb-C mice IP injected with PNA TAR -S-S-penetratin in saline solution were euthanized at different time points. A single dose of 125I-labeled PNA was IP administered to Balb/C mice as described in Materials and Methods. Mice were euthanized at different time points and the radioactive PNA compounds in different organs and tissues were monitored. Accumulation of radioactivity in individual organs or tissues was calculated as a percent of injected activity per gram tissue (%IA/g). Maximum accumulation is expressed as a percent of injected activity per gram (%IA/g). a = pharmacokinetic coef cient for maximum accumulation by the rapid-release pathway; b = pharmacokinetic coef cient for maximum accumulation by the slow-release pathway.
the maximum accumulation of PNA TAR-penetratin conjugate occurred in the intestine, followed, in order, by the liver, blood, and spleen ( Fig. 2A) . Accumulations of these compounds were lowest in the brain and skeletal muscle.
We noted a similar pattern when these compounds were administered orally (Fig. 2B) . Surprisingly, the biodistribution of the uptake of unconjugated naked PNA TAR was similar to that of PNA TAR -CPP conjugates. Although cellular uptake of unconjugated naked PNA TAR was negligible in a or tissue (Fig. 2) . We observed that signi cant amounts of IP-administered PNA TAR -CPP conjugates, as well as naked PNA TAR , had been rapidly taken up and distributed in all mouse organs and tissues except the brain and skeletal muscle ( Fig. 2A) . We recorded maximum accumulation of these compounds within one hour after their administration; after that, the accumulated radioactivity declined with time. The accumulations of both naked PNA TAR and PNA TAR -Tat conjugate were higher in the kidneys than in other organs, while The half-time of the biphasic clearance pattern is comprised of a fast-release (T1) and a slow-release component (T2). The half-time of the biphasic clearance pattern, comprised of a fast-release (T1) and slow-release component (T2). For each time point, four mice were injected. The values in italics in parenthesis are the results of uncertainties in the tting procedure by a two-component function, as noted in the Results. The goodness of t (R 2 ) values ranged from 0.85 to 1. Each "X" indicates that, in the speci ed organs or tissues, no signi cant data could be obtained to determine b and T2 values for PNA TAR and its CPP conjugates.
PNA TAR that accumulated in organs as rapid-clearance component "a" varied from 0.09 to 18.45, the lowest being in the brain and the highest in the intestine. PNA TAR -Tat and PNA TAR -penetratin displayed an approximately similar pattern, with varying degrees of accumulation as a rapid-clearance component in different organs and tissues. Slow-clearance components of all three compounds were highest in the kidney, ranging from 2.7% for PNA TARpenetratin to 13.3-14.7% for naked PNA TAR and PNA TAR -Tat conjugate (Table 1) . In other organs and tissues, the extent of accumulation of the slow-release components was lower and signi cantly varied for each of the test compounds. Half-time values (T1) for PNA TAR and its peptide conjugates varied marginally in different organs and tissues except the kidney, where PNA TAR -Tat had the highest T1 value, 10.4 hours, albeit with very large standard deviation. PNA TAR -penetratin and naked PNA TAR had T1 values of 6.4 and 1.33 hours, respectively ( Table 1 ). The half-time T2 values of the slow-clearance components of all three test compounds were signi cantly large ( Table 2 ). The T2 value for PNA TAR -penetratin in blood was signi cantly higher than those for the other two test compounds. In the spleen, the %AA and the T1 and T2 values for naked PNA TAR were greater than the values for the other two test compounds. It would be interesting to determine whether any of the test compounds elicit an immunological response by examining stimulation of spleenocytes in in vitro cell culture upon in vivo exposure to these compounds.
The biphasic clearance data and the respective halftime values for orally administered compounds are shown, respectively, in Tables 3 and 4 . The distribution of the test compounds administered via gavage displayed a very different pattern from that of IP-administered compounds (Table 3 ). The extrapolated value of "a" obtained from the y-intercept of the sigma plot was large in the stomach and intestine. This suggests that a signi cant portion of the administered compound either remained unabsorbed in the cell-culture system, its uptake, biodistribution, and retention in vivo was signi cant, suggesting the possible involvement of some unknown mechanism that may facilitate its uptake and biodistribution.
Clearance pro le of PNATAR and its CPP conjugates after IP administration or gavage
We monitored the clearance pro les of IP and orally administered PNA TAR and its CPP conjugates from the different organs and tissues as a function of time. We observed biphasic clearance of both PNA TAR and its CPP conjugates in all of the organs and tissues examined. Figure 3 shows the representative clearance pattern of PNA TAR -penetratin from blood. As shown in Fig. 3A , a signi cant portion of the IP-administered PNA TAR -penetratin accumulated in the blood was cleared rapidly with a half-time (T1) . We noted similar biphasic clearance pro le for orally administered PNA TAR -penetratin from the blood (Fig. 3B) .
The pro le of the clearance of each test compound from different mouse organs was also biphasic, albeit with variable T1 and T2 values and clearance rate constants. Results obtained with each test compound administered by the IP route or gavage are depicted, respectively, in Tables  1-4. Table 1 shows the percent of IP-administered radioactivity (%AA) of each compound subject to rapid or slow clearance. Tables 3 and 4 depict half-times of both components (T1 and T2) from the respective organs and tissues. As shown in Table 1 , the percent of IP-administered naked blocks Tat-mediated transactivation of HIV-1 transcription and replication (Kaushik et al., 2002b . Besides antiviral activity, PNA TAR -CPP conjugates also have potent anti-HIV-1 virucidal activity that, on brief exposure, renders HIV-1 virions noninfectious. The cellular uptake of naked PNAs in cell culture is negligible. However, after conjugation with CPP, they are rapidly internalized into cells and interact with their target sequences. stomach or intestine and excreted via the fecal route or was absorbed and rapidly cleared. However, the rst possibility must be ruled out since there was no signi cant difference in the fecal excretion pattern of all PNA compounds administered by either route. In this context, the slow-release component "b" is of interest. It is the component that is expected to have therapeutic value with regard to these compounds.
Stability of IP-administered PNA TAR -penetratin conjugate in mouse organs
After IP injection, PNA TAR conjugate was isolated from kidneys and livers collected from euthanized mice at different times. After their binding to a 32 P-labeled target sequence (82 mer TAR DNA), the isolated PNA TAR conjugates were subjected to mass spectroscopy and a gel-retardation assay. Mass spectroscopy of the conjugate isolated from the liver and kidney indicated several mass peaks of the conjugate due to truncation of its peptide components (Fig. 4A) . Gel retardation of the 32 P-labeled target sequence suggested that the PNA component of the conjugate had remained intact (Fig. 4B) . PNA alone has been shown to be highly stable in tissue and cellular extracts since it is completely resistant to proteases and nucleases (Demidov et al., 1994; Jansen and Richardson 2000) .
Excretion of the conjugates
As described in Methods, we also measured the excretion of 125 I-labeled test compounds in urine and feces. The rates of urinary excretion of both naked PNA TAR and PNA TAR -Tat were lower than the rate of excretion of PNA TAR -penetratin conjugate (Table 5) . During the rst 4 h after IP administration, about 45% of PNA TAR -penetratin was excreted in the urine, while only 9% of PNA TAR -Tat and 10% of naked PNA were excreted; 8.6% of orally administered PNA TAR -penetratin was excreted. In contrast, there was no signi cant difference in the fecal excretion pattern of any of the PNA compounds administered by either route (Table 6 ).
Discussion
The potential of PNAs as antisense therapeutic agents has been recognized for quite some time. However, their solubility and cellular uptake has been a consistent impediment to their development for this purpose (Wittung et al., 1995) . Several efforts to improve their in vitro cellular uptake by conjugating PNAs with various cell-permeating peptides, lipids, or antibiotics have had mixed results (Koppelhus and Nielsen, 2003) . Although it has been reported that naked PNA can be taken up in vivo (McMahon et al., 2002 , Pierce et al., 2005 , Boffa et al., 2007 , its cellular uptake in in vitro cell-culture systems has been negligible (Kaushik et al., 2002a; Chaubey et al., 2005; Tripathi et al., 2005) .
Earlier, we demonstrated that PNA TAR targeted to the TAR element of HIV-1 LTR ef ciently prevents Tat-TAR interaction by sequestering the TAR sequence and blocks Tat-mediated transactivation of HIV-1 LTR transcription (Mayhood et al., 2000) . We further demonstrated that PNA TAR conjugated with CPP ef ciently enters cells and Following IP injection of the conjugate, mice were euthanized at different times, and the conjugate accumulated in kidney and liver tissue was isolated. Mass spectrometry analysis of the isolated compound from kidney following 6 h of IP administration (top panel A) was done on an Applied Biosystems 4700 Proteomics Analyzer 7000. For gel retardation (bottom panel B), 5'-32 P-labeled 82-mer TAR-DNA (5 nM) was incubated with the isolated PNA TAR conjugate in the binding buffer (50 mM Tris.HCl, pH 7.8, and 5 mM MgCl 2 ) for 30 min at room temperature. Gel loading dye containing 0.25% bromophenol blue and 30% glycerol was added to it and loaded on a native 6% polyacrylamide gel. The gel was run for 3 h at 150V in 1X Tris-borate-EDTA buffer, dried, and subjected to Phosphor-Imager analysis (Molecular Dynamics).
IP administration of
125 I-labeled PNA TAR and its CPP conjugates demonstrated that both unconjugated and conjugated PNA TAR are taken up from the peritoneal cavity to different organs and tissues. However, overall accumulation and the clearance pro les of these compounds varied in different organs, probably due to differences in membrane transport systems and their cellular constitution (McMahon et al., 2002; Trehin et al., 2004) . The maximum accumulation of PNA compounds occurred at all sites within the rst 2-3 h after administration, irrespective of whether it was done by IP injection or oral gavage (Fig. 2) . The clearance pattern of each accumulated PNA TAR derivative displayed a biphasic pro le consisting of rapid-clearance and slow-clearance To evaluate in vivo uptake and distribution of PNA TAR and its CPP conjugates, we introduced 125 I radiolabel into the PNA moiety via Tyr residue that had been added in tandem at the N-terminal of PNA during synthesis. The penetratin or Tat peptide to which naked PNA TAR was conjugated is devoid of Tyr residue, so that radio-iodination is selective to the Tyr-PNA TAR moiety of the conjugate. The radiolabeled naked Tyr-PNA TAR is stable when incubated with mouse blood serum or liver tissue extract for 24 hours at room temperature (unpublished results). We also evaluated the stability of the peptide moiety of the labeled conjugate, which, on cellular uptake, was either shortened or cleaved by cellular proteases (Fig. 4) . Groups of three male Balb/C mice were given 125 I-labeled naked PNA or PNA conjugates and placed in separate polycarbonate cages lined with thick Whatman lter papers. Animals were transferred to fresh cages at an interval of 4 hours. The lter papers soaked in the urine were collected, cut into pieces, and counted for radioactivity. Feces were counted without further processing. Values are expressed as the percent of administered activity (%AA) excreted in urine or feces. Groups of three male Balb/C mice were given 125 I-labeled naked PNA or PNA conjugates and placed in separate polycarbonate cages lined with thick Whatman lter papers. Animals were transferred to fresh cages at an interval of 4 hours. The lter papers soaked in the urine were collected, cut into pieces, and counted for radioactivity. Feces were counted without further processing. Values are expressed as the percent of administered activity (%AA) excreted in urine or feces. components (Fig. 3) . The biological half-lives of PNA compounds in the two phases are represented by T1 and T2 (Fig. 3) . The slow-component pathway (T2) of any potential drug candidate is the desired mode of clearance because it ensures longer biological residence of the drug in the body, extending the time of its pharmacological effectiveness. Surprisingly, the distribution, and clearance pro le of naked PNA in mice after IP administration did not signi cantly differ from those of PNA-CPP conjugates. In an earlier study, we showed that in a cell-culture system, the cellular uptake of naked PNA is negligible . However, after the conjugation of naked PNA with CPP, cellular uptake of the PNA-CPP conjugate was rapid and homogenous . The higher T2 values observed for PNA TAR -penetratin in kidney and blood suggest that after initial rapid internalization of this compound, its peptide moiety may have been cleaved, resulting in slow clearance from the cells. Similarly, higher or somewhat similar T2 values for PNA TAR -Tat in liver, intestine, and kidney (Table 2) could be possible following degradation of the Tat peptide moiety of the conjugate. Tat peptide, being rich in Arg and Lys residues (Fig. 1) , could be susceptible to trypsin-like proteases in mouse organs (Walsh, 1970; Zamecnik et al., 1986) .
We used PNA TAR -penetratin (S-S) and PNA TAR-penetratin (-O-), as well as naked PNA TAR , in our pharmacokinetic studies of compounds administered by the oral route. Our nding that all three compounds were signi cantly taken up and distributed throughout the major internal organs of mice after gavage indicates the existence of an uptake mechanism for these conjugates in the epithelial membrane of the intestine. This initial study of PNA TAR conjugated to penetratin by -S-S-linker was encouraging in that all organs and tissue except the spleen and skeletal muscle displayed a slow-release pathway. However, when a stable ethylene glycol linker (-O-) was used in place of the cleavable -S-Slinker, no signi cant change in clearance pro le was noted in most of the organs and tissues studied (Table 4) .
The peptide transporter system in the epithelial or brush border membranes of the intestine that are implicated in the transport of di-, tri-or tetra-peptides may have an important function in the uptake of PNA TAR -CPP conjugates administered via the oral route (Fei et al., 1994; Liang et al., 1995) . This system facilitates the uptake of dietary protein by the small intestine, as well as the absorption of orally active β-lactam antibiotics and other peptide-like drugs (Liang et al., 1995) . In the kidney, peptide transporters help to reabsorb ltered peptides, peptide-derived antibiotics, and peptidomimetics drugs (Liang et al., 1995; Bordin et al., 2002) . It is possible that the CPP moiety of the PNA-penetratin conjugate undergoes partial proteolysis at the brush-border membrane, resulting in a PNA TAR -CPP conjugate with a reduced length of CPP that may be an ideal substrate for peptide transporters. Although unconjugated naked PNA TAR is taken up and distributed in different organs irrespective of the route of administration, the extent of the uptake and distribution of its CPP conjugates is higher than that of the naked PNA TAR . The possible mechanism of uptake of naked PNA could be via unknown Toll-like receptors induced or present on the surface of intestinal epithelial cells (Furuka et al., 2006) . It should be possible to deliver anti-HIV-1 PNAs speci cally in the lymph nodes/macrophages by conjugating them with ligands that are exclusively recognized by macrophage receptors such as formyl peptide receptors, mannose receptors and Fc receptors. A natural ligand, fMLF (formyl methionyl-leucylphenylalanine) conjugated with PEG nanocarrier has been shown to speci cally accumulate in the IP macrophages (Wan et al., 2007) . This could be a potential therapeutic strategy to deliver anti-HIV-1 PNAs speci cally to macrophages to achieve their effective concentrations in the cells and block HIV-1 replication and production of virion particles. We have recently shown that PNA TAR -CPP conjugates are not toxic up to a single 300-mg dose/kg of body weight of mice. Repeated doses of 100 mg/kg of body weight are also well tolerated (Chaubey et al. 2008) . The reduced in vivo toxicity and stability of PNA TAR and its CPP conjugates, as well as their slow release and clearance from different organs, suggest the possible therapeutic potential of these compounds.
